Metabolic and Vascular Effects of Statins in Untreated Dyslipidemic Diabetic Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00854503
Recruitment Status : Completed
First Posted : March 3, 2009
Last Update Posted : May 12, 2011
Information provided by:
University of Rome Tor Vergata

Brief Summary:
Type 2 diabetes (T2D), because of impaired glucose regulation and consequent hyperglycemia, promotes the development of coronary heart disease. Secondary dyslipidemia is often associated with T2D and enhances the risk of cardiovascular complications. HMG-CoA reductase inhibitors (statins) are selectively administrated for the treatment of dyslipidemia, leading to a significant reduction of cardiovascular risk. More recently, revisions to guidelines have established a lower therapeutic LDL cholesterol goal for diabetic patients, requiring the administration of higher dose of statin. However, it is unclear whether high dose statin therapy could affect glycemic control in diabetic patients. Moreover, data regarding the effects of statins on insulin-resistance and endothelial function are controversial.

Condition or disease Intervention/treatment Phase
Type 2 Diabetes Diabetic Dyslipidemia Drug: Simvastatin Drug: Rosuvastatin Phase 3

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Study Start Date : September 2008
Actual Primary Completion Date : March 2010
Actual Study Completion Date : December 2010

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: Simvastatin
Simvastatin 20 mg/day
Drug: Simvastatin
20 mg/day in one oral administration

Active Comparator: Rosuvastatin
Rosuvastatin 20 mg/day
Drug: Rosuvastatin
20 mg/day in one oral administration.

Primary Outcome Measures :
  1. Glucose tolerance assessed by HbA1c and fasting glucose [ Time Frame: 1, 6, 12 months ]

Secondary Outcome Measures :
  1. insulin-resistance assessed by clamp. Endothelial function assessed by FMD %. Inflammatory status assessed by biochemical markers. [ Time Frame: 1, 6, 12 months. ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   50 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Type 2 diabetes in good glycemic control, treated with metformin alone.
  • Untreated dyslipidemia.
  • BMI <30.

Exclusion Criteria:

  • History of cancer.
  • History of cardiovascular diseases.
  • Any other acute or cronic illness which requires administration of steroids or other drugs able to interfere with glucose metabolism.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00854503

University of Rome Tor Vergata
Rome, Italy, 00133
Sponsors and Collaborators
University of Rome Tor Vergata

Responsible Party: Davide Lauro, University of Rome Tor Vergata Identifier: NCT00854503     History of Changes
Other Study ID Numbers: 131/08
First Posted: March 3, 2009    Key Record Dates
Last Update Posted: May 12, 2011
Last Verified: January 2011

Keywords provided by University of Rome Tor Vergata:
Statins administration in diabetic dyslipidemia

Additional relevant MeSH terms:
Lipid Metabolism Disorders
Metabolic Diseases
Rosuvastatin Calcium
Anticholesteremic Agents
Hypolipidemic Agents
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Enzyme Inhibitors